| Total: $1,062.94 | ||||
Company | Type Of | Number Of | Amount | Investors; Placement Agents; Details |
| | ||||
Adventrx | Private placement of stock | 14.545S | $40 | Accredited and institutional investors purchased the stock at $2.75 per share; ThinkEquity Partners LLC was lead placement agent; Fortis Securities LLC was co-agent (11/3) |
Akesis | Private placement of stock and warrants | 5.85S and 0.878W | $3.51 | The shares were sold at $0.60 each; warrants are exercisable at the same price; $3M of the investment was provided by Avalon Ventures VII LP (11/27) |
Anesiva Inc. | Registered direct offering | 7S | $44.8 | The registered stock was sold to institutional investors at $6.40 per share, the Nov. 21 closing price; Lazard Capital Markets LLC was lead placement agent; Needham & Co. LLC and Rodman & Renshaw LLC were co-agents (11/22) |
Avanir | Private placement of stock and warrants | 5.265S and 1.053W | $15 | Institutional investors purcahsed the stock at $2.85 per share; the one-year warrants are exercisable at $3.30 per share; Rodman & Renshaw LLC was placement agent (11/3) |
Biofusion plc | Private placement of stock | 5.35S | £7.75 ($15.3) | Shares were sold at 145 pence each in a deal fully underwritten by Nomura Code Securities (11/30) |
BioMS | Private placement of stock and warrants | 6.129S and 3.065W | C$20.9 ($18.3) | Units consisting of one share and one-half warrant were sold at C$3.41 each; full four-year warrants are exercisable at C$4 per share; Versant Partners Inc. and Rodman & Renshaw were co-lead placement agents; Fondsfinans ASA was co-agent (11/24) |
BioTie | Private placement of stock | 25.49S | €13 ($17.2) | Investors including Pequot Capital, Dreadnought Finance Oy, Thominvest Oy and SITRA purchased the stock at €0.51 per share; another €7.5M could be added to the deal by retail investors (11/30) |
Cangene | Bought-deal financing | 4.375S | C$35.4 ($31) | Underwriters led by GMP Securities LP and including TD Securities Inc., Scotia Capital Inc. and Sprott Securities Ltd. purchased the stock at C$8.10 per shares; totals do not include 5.625M shares sold in the deal by existing shareholders (11/21) |
Clinuvel | Rights issue and private placement | 91.4S | A$35.2 ($27.1) | Clinuvel raised A$30.5M in a rights issue and A$4.7M in a private placement; shares were sold at A$0.385 in each deal (11/1) |
CollaGenex | Private placement of stock | 3.5S | $45.5 | Institutional and other investors are purchasing the registered shares at $13 each, a 2% discount to the prior day's close; Lazard Capital Markets LLC was placement agent (11/16) |
Corcept | Private placement of stock | 3S | $3 | Paperboy Ventures LLC led the financing, which included Sutter Hill Ventures and three members of Corcept's board (11/15) |
Crucell NV | Private placement of stock | ND | €80 ($105) | The funds were raised as part of Crucell's acquisition of SBL Vaccin AB; specific details on the financing were not disclosed (11/21) |
Cytogen | Private placement of stock and warrants | 7.09S and 3.546W | $20 | Institutional investors purchased units at $2.82 each; the five-year warrants are exercisable at $3.32 per share (11/7) |
Discovery | Private placement of stock and warrants | 4.6S and 2.3W | $10 | One institutional investor purchased the stock at $2.16 per share, a 5% discount to a five-day average; the five-year warrants are exercisable at $3.18 per share; Jefferies & Co. Inc. was placement agent (11/22) |
Dyadic | Private placement of stock and warrants | 2.787S and 0.557W | $13 | The stock was sold at $4.68 per share; the 3.5-year warrants are exercisable, after 180 days, at $6.33 per share; Cowen and Co. LLC was placement agent (11/20) |
Hollis-Eden | Private placement of stock and warrants | 4S and 0.8W | $26 | The registered shares were sold at $6.50 each; the four-year warrants are exercisable at $8.75 per share; Rodman & Renshaw LLC was lead placement agent; Canaccord Adams Inc. was co-agent (11/8) |
Introgen | Private placement of stock | 1.32S | $6.1 | An institutional investor purchased the registered shares; Mulier Capital was placement agent (11/7) |
Lumera | Private placement of stock and warrants | 2.825S and 0.424W | $16.95 | The shares were sold at $6 each; the five-year war- rants are exercisable at $6.25 per share; the investment was led by Robert W. Baird & Co. (11/8) |
Metabasis | Committed equity facility | N/A | N/A | Kingsbridge Capital Ltd. committed to buy up to $50M in Metabasis stock over three years at a dis-count of 6% to 10%; Metabasis will determine the timing and amount of any sale (11/2) |
Migenix Inc. | Bought-deal financing | 16.75U | C$10 ($8.74) | A Canadian investment dealer purchased the units at C$0.60 per unit; each consists of one common share and one-half of a warrant; each whole war- rant is exercisable at C$0.80 per share (11/16) |
Millennium | Sale of convertible notes | N/A | $250 | The 2.25% notes are due in 2011; they are convertible into common shares at an intial price of $15.47 per share; Morgan Stanley & Co. Inc. and JP Morgan Securities Inc. are joint managers for the deal; totals include their purchase of $25M in the notes per an overallotment option (11/9) |
Neurochem | Private | N/A | $42.09 | The 6% notes due in 2026 carry a conversion premium of 20%, initially $19.72 per share; totals include the purchase of $2.085M in notes by UBS Securities LLC per its overallotment option (11/3) |
Neuro-Hitech | Private placement of stock and warrants | 0.605S and 0.302W | $3.1 | Up to 604,878 shares and 302,439 warrants are being sold; the exact number of shares and warrants will equal the greater of $5.125 per share or a 20% discount to a 20-day trading average prior to its acquisition of Q-RNA Inc.; the warrants will be exercisable at $7 per share (11/17) |
Nymox | Private | ND | $13 | Institutional investors purchased the shares at a 3% discount to the market price; the number of shares and the price were not disclosed (11/29) |
Pipex | Private placement of stock and warrants | 13.7S and 6.8W | $13.7 | Accredited Venture Capital LLC provided $4.5M in funding prior to Pipex's merger with Sheffield Pharmaceuticals Inc.; the second deal totaling $9.2M involved the sale of 13.7M shares and 6.8M warrants exercisable at $0.74 per share (11/28) |
Prana | Private | 21.8S and 4.35W | A$7.8 ($6.1) | Shares are being purchased at A$0.357 per share (about $2.80 per ADR); the options are exercisable at A$0.446 per share (about $3.40 per ADR) (11/21) |
Protox | Private placement of stock and warrants | 18.35S and 9.175W | C$9.17 ($8) | Units consisting of one share and half a warrant were sold at C$0.50 each; each one-year warrant is exercisable at C$0.65 per share; Jennings Capital Inc. and Canaccord Capital Corp. co-led the deal (11/29) |
Regeneron | Private placement of stock | 7.6S | $175 | Morgan Stanley & Co. Inc. purchased the registered shares at $23.03 each (11/13) |
SR Pharma pl (UK; AIM:SPA) | Private placement of stock | 20S | £3.8 ($7.2) | Institutional investors, including some existing shareholders, purchased the stock at 19 pence per share (11/6) |
Tm Bioscience | Credit facility | N/A | N/A | Laurus Master Fund Ltd. provided the 7% credit facility, payable initially with stock at C$0.71 per share; the facility matures on Aug. 31, 2007 (11/28) |
TopoTarget | Private placement of stock | 4.153S | DKK126.7 ($22.5) | The stock was sold at DKK30.5 per share; ABN AMRO Rothschild and Handelsbanken Capital Markets were placement agents (11/28) |
Vasogen Inc. | Private placement of stock and warrants | 43.2S and 21.6W | $20.3 | Units consisting of a share and half a warrant were sold at $0.47 each; 80% of the warrants are exercisable for five years at $0.63 per share; 20% are exercisable for six months at $0.53 per share; Rodman & Renshaw LLC was placement agent (11/9) |
Virax | Rights issue and placement | 13.5S | A$2.36 ($1.85) | Shareholders subscribed to A$0.56M in stock, and A$1.80 million was committed by way of shortfall placement agreements with Tricom Equities Ltd. (11/9) |
Vivus Inc. | Registered direct offering | 9.6S | $33.6 | The registered shares were purchased at $3.50 each; Caxton Advantage Life Sciences Fund LP led the financing, which also included Euclid SR Partners, OrbiMed Advisors LLC, Franklin Templeton Investments and Quogue Capital LLC (11/20) |
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; HSE = Helsinki Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||